Affiliation:
1. A.I. Evdokimov Moscow State Medico-Stomatological University
2. A.S. Puchkov Emergency Medical Care Station. Moscow, Russia
Abstract
The paper reviews the clinical practice potential of a combined action antihypertensive medication urapidil for the treatment of patients with acute elevation of blood pressure (BP) and confirms urapidil effectiveness and good tolerability. Urapidil action mechanisms, pharmacodynamics, and pharmacokinetics are discussed, together with the results of the key clinical trials which have demonstrated antihypertensive effectiveness and safety of this agent. Additional beneficial effects of urapidil, such as reduction of the increased pulmonary artery BP and improvement of bronchial conductivity, are also described.
Subject
Cardiology and Cardiovascular Medicine
Reference35 articles.
1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–23.
2. Shal’nova SA, Kukushkin SK, Manoshkina EM, et al. Arterial hypertension and adherence to therapy. Vrach 2009; 12: 39–2. Russian (Shal'nova S. A., Kukushkin S. K., Manoshkina E. M. i dr. Arterial'naya gipertenziya i priverzhennost' terapii. Vrach 2009; 12: 39–2).
3. Hypertensive crises. Edited by Tereshhenko SN, Plavunova NF. M., MEDpressinform 2013; 207 r. Russian (Gipertonicheskie krizy. Pod red. Tereshchenko S. N., Plavunova N. F., M., MEDpress-inform 2013; 207 s).
4. Leonetti G, Terzoli L, Zanchetti A. Systemic haemodynamic and humoral changes during urapidil treatment in hypertensive patients. J Hypertens 1988; 6 (2): 25–9.
5. Langtry HD, Mammen GJ, Sorkin EM. Urapidil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs 1989; 38: 900–40.